Identifying genes that influence tumor growth and immune response in cancer.
Official title: Spatial functional genomics to identify regulators of the tumor microenvironment and cancer immunity
Funded at Icahn School of Medicine at Mount Sinai · NIH-10931761 · Data updated 2026-11-12
This study is looking at how the environment around tumors affects cancer growth and how well treatments, especially immunotherapy, work, with the hope of finding new ways to make these treatments more effective for patients like you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $964,277 |
| NIH project number | 5U01CA282114-02 |
| Project ID | NIH-10931761 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with breast cancer or other cancers that are influenced by the tumor microenvironment.
✕Less likely to help
Patients with tumors that do not interact significantly with the immune system or those with non-cancerous conditions may not benefit from this research.
What this research studies
This research investigates how the tumor microenvironment (TME) affects cancer growth and response to treatments, especially immunotherapy. By using a novel spatial functional genomics platform called Perturb-map, the study aims to identify specific genes that regulate the composition of the TME and contribute to tumor resistance against immune attacks. The goal is to uncover vulnerabilities in the tumor environment that can be targeted to enhance the effectiveness of cancer treatments. Patients may benefit from insights that could lead to improved therapies tailored to their specific tumor characteristics.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the immune system's ability to fight cancer.
How similar studies have gone: Previous research has shown promising results in targeting the tumor microenvironment to improve cancer therapies, indicating that this approach has potential for success.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Brown, Brian D — Icahn School of Medicine at Mount Sinai
- Study coordinator: Brown, Brian D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.